These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 6316304)
41. The Janus face of dendritic cells in cancer. Chaput N; Conforti R; Viaud S; Spatz A; Zitvogel L Oncogene; 2008 Oct; 27(45):5920-31. PubMed ID: 18836473 [TBL] [Abstract][Full Text] [Related]
42. [Immunosuppression mechanism affecting the development of neoplasms]. Rupniewska ZM; Kurowska M Pol Tyg Lek; 1980 Mar; 35(12):455-7. PubMed ID: 6966796 [No Abstract] [Full Text] [Related]
43. Cytokine-based transformation of immune surveillance into tumor-promoting inflammation. Mumm JB; Oft M Oncogene; 2008 Oct; 27(45):5913-9. PubMed ID: 18836472 [TBL] [Abstract][Full Text] [Related]
44. Biological markers of early health effects in the assessment of the risk of cancer in people exposed to environmental carcinogens. Indulski JA; Lutz W; Krajewska B Pol J Occup Med Environ Health; 1993; 6(2):149-56. PubMed ID: 8219906 [TBL] [Abstract][Full Text] [Related]
45. Surveillance against tumors--is it mainly immunological? Klein G; Klein E Immunol Lett; 2005 Aug; 100(1):29-33. PubMed ID: 16129497 [TBL] [Abstract][Full Text] [Related]
46. [The cellular immunity and cyclonucleotide level in the immunoregulatory cells of patients with bronchial asthma and chronic bronchitis]. Strigin VM; Kolesnikov AP Ter Arkh; 1994; 66(1):72-5. PubMed ID: 7908463 [TBL] [Abstract][Full Text] [Related]
47. [Role of the microenvironment in determining the typology of pulmonary carcinoma]. Gabbrielli S Arch De Vecchi Anat Patol; 1983 Jul; 65(2-3):239-50. PubMed ID: 6680288 [No Abstract] [Full Text] [Related]
49. Incorporating pathologists' criteria of malignancy into the evolutionary model for cancer development. Fischer AH; Young KA; DeLellis RA J Cell Biochem; 2004 Sep; 93(1):28-36. PubMed ID: 15352159 [TBL] [Abstract][Full Text] [Related]
50. Immunological synapses in infectious diseases. Siqueira-Batista R; Geller M; Gomes AP Braz J Infect Dis; 2007 Feb; 11(1):1. PubMed ID: 17625715 [No Abstract] [Full Text] [Related]
51. [Human tumor immunology. Potential possibilities in immunologic diagnosis]. Wigzell H Tidsskr Nor Laegeforen; 1971 Aug; 91(23):1687-9. PubMed ID: 4938867 [No Abstract] [Full Text] [Related]
52. Immunoregulation of carcinogenesis: past, present, and future. Kripke ML J Natl Cancer Inst; 1988 Jul; 80(10):722-7. PubMed ID: 3290496 [TBL] [Abstract][Full Text] [Related]
53. How many cancers are reversible or suppressible? Metcalf D Pathology; 1983 Jan; 15(1):1-3. PubMed ID: 6222281 [No Abstract] [Full Text] [Related]
54. Blebbishield emergency program: an apoptotic route to cellular transformation. Jinesh GG; Kamat AM Cell Death Differ; 2016 May; 23(5):757-8. PubMed ID: 26967969 [No Abstract] [Full Text] [Related]
55. Aging and Cancer: The Waning of Community Bonds. Laconi E; Cheri S; Fanti M; Marongiu F Cells; 2021 Aug; 10(9):. PubMed ID: 34571918 [TBL] [Abstract][Full Text] [Related]
56. Summation and synthesis: from the immunology point of view. Heppner GH Adv Exp Med Biol; 1993; 330():315-20. PubMed ID: 8368140 [No Abstract] [Full Text] [Related]
59. Multiple solutions of a model describing cancerous growth. Qi AS Bull Math Biol; 1988; 50(1):1-17. PubMed ID: 3370368 [No Abstract] [Full Text] [Related]
60. [The immunological system and neoplastic diseases]. Ben-Bassat Y Harefuah; 1971 Feb; 80(3):152-4. PubMed ID: 5099258 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]